GleamWall
中文EN

IOVA IOVANCE BIOTHERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1425205 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY51.3%
TTM net income YoY44.5%
TTM EPS YoY58.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin53.2%
Operating margin-60.8%
Net margin-58.2%
FCF margin-57.0%
EBITDA margin-54.0%

Returns

ROE-29.1%
ROA-23.3%
ROIC (approx.)-28.0%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets18.0%
Debt / equity0.00x
Current ratio5.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue6.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$121.47M$99.31M$71.43M$86.77M$67.45M$59.95M$49.32M$73.69M
Cost of revenue$48.03M$43.59M$42.50M$43.11M$38.48M$48.88M$42.72M$37.79M
Gross profit$73.44M$55.72M$28.93M$43.66M$28.98M$11.07M$6.61M$35.91M
R&D expense$49.34M$58.85M$62.49M$71.20M$75.17M$77.93M$75.97M$71.01M
SG&A expense$38.58M$39.27M$38.95M$36.40M$34.55M$37.57M$43.80M$42.32M
Operating income-$23.97M-$51.91M-$81.04M-$73.46M-$94.90M-$113.77M-$121.22M-$86.58M
Pretax income-$21.66M-$48.69M-$79.71M-$71.72M-$93.66M-$109.67M-$118.00M-$77.00M
Income tax$614,000-$1.37M-$665,000$184,000-$2.40M$1.99M-$1.84M$1.56M
Net income-$22.27M-$47.31M-$79.05M-$71.90M-$91.25M-$111.66M-$116.16M-$78.56M
EBITDA-$14.47M-$42.41M-$78.22M-$69.74M-$85.89M-$104.42M-$118.65M-$83.30M
EPS (basic)-0.05-0.11-0.19—-0.25-0.33-0.36—
EPS (diluted)-0.05-0.11-0.19—-0.25-0.33-0.36—
Weighted avg. shares (diluted)455.92M450,189418,511—364.04M334,511322,868—
Balance sheet
Cash & equivalents$57.93M$110.77M$196.51M$163.08M$158.13M$132.47M$171.67M$122.05M
Short-term investments$318.39M$186.91M$116.94M$133.90M$142.67M$168.71M$188.04M$208.09M
Receivables$106.99M$102.12M$81.76M$82.45M$66.76M$59.94M$70.94M$69.34M
Inventory$55.22M$55.59M$58.38M$51.68M$51.71M$49.83M$65.55M$51.52M
Current assets$549.63M$464.26M$466.50M$442.69M$429.09M$422.50M$512.65M$457.02M
PP&E, net$129.31M$131.46M$131.39M$131.11M$126.65M$122.47M$111.58M$109.08M
Intangibles$259.21M$263.89M$269.10M$279.32M$285.21M$296.25M$285.36M$282.40M
Total assets$991.21M$915.53M$925.66M$913.17M$904.95M$907.44M$966.74M$910.43M
Current liabilities$105.77M$106.85M$129.42M$138.36M$125.78M$129.16M$122.69M$122.34M
Total liabilities$178.55M$179.49M$203.91M$214.59M$202.66M$208.95M$198.88M$200.02M
Shareholders' equity$812.66M$736.04M$721.75M$698.58M$702.29M$698.49M$767.87M$710.40M
Shares outstanding462.54M452.97M438.11M411.94M385.46M341.92M333.93M305.25M
Cash flow statement
Operating cash flow-$4.47M-$60.84M-$72.07M-$52.56M-$78.70M-$67.45M-$103.69M-$73.30M
Capital expenditure$4.74M$5.44M$6.61M$9.32M$10.84M$7.46M$6.21M$4.17M
Free cash flow-$9.21M-$66.28M-$78.68M-$61.88M-$89.55M-$74.91M-$109.91M-$77.46M
Investing cash flow-$134.65M-$74.05M$11.39M$775,000$17.01M$13.84M$15.87M$23.68M
Financing cash flow$86.28M$49.29M$94.33M$56.17M$88.06M$13.23M$143.31M$2.31M
Depreciation & amortization$9.50M$9.50M$2.82M$3.72M$9.01M$9.35M$2.57M$3.27M
Stock-based compensation$11.83M$11.73M$11.27M$11.82M$11.90M$14.94M$22.91M$30.98M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.